Tue 18'th Sep 2018
Tekla Life Sciences Investors Stock Analysis
Technical stock analysis for Tue 18'th Sep 2018
|Shorts||0.44% ( 2013-01-15 )|
Tekla Life Sciences Investors gained 1.49% in the last trading day, rising from $19.47 to $19.76 The price has fallen in 7 of the last 10 days and is down by -3.09% for this period. Volume fell in the last day by -8 083 shares, and in total, 46 629 shares bought and sold for approximately $921 389.00. You should take into consideration that a falling volume on higher prices causes divergence and may be an early warning about possible changes for the next couple of days.
Tekla Life Sciences Investors lies in the middle of a weak rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 4.46% during the next 3 months and, with 90% probability hold a price between $20.04 and $21.61 at the end of this period.
A buy signal was issued from a pivot bottom point on Monday September 17, 2018, which indicates further gains until a new top pivot has been found. Some negative signals were issued as well, and these may have some influence on the near short-term development. Tekla Life Sciences Investors holds a buysignal from the short-term moving average; at the same time, however, a sales signal from the long-term average. Since the longterm average is above the short-term average there is a general sales signal in the stock. On further gains, the stock will meet resistance from the long-term moving average at $19.91. On a fall, the stock will find some support from the short-term average at $19.63. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sales signal and strengthen the general signal. Volume fell during the last trading day while the price increased. This causes a divergence and may be considered as an early warning, but it may also not.
Relative Strength Index (RSI)
RSI14 is 45 and the stock is currently not being overbought or oversold
Support & Resistance
Tekla Life Sciences Investors finds support from accumulated volume at $19.75.
In general the stock tends to have controlled movements, but the low liquidity has increased the risk substantially.
Our recommended stoploss: $18.73 (-5.21%) (This stock has low daily movements and this gives low risk. There is a buy signal from pivot bottom found 1 days ago.)
Very Low Low Medium High Very High
Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for this stock to perform well in the short-term. We have upgraded our recommendation for this stock since last evaluation from a Sell Candidate to a Buy Candidate.Click for Top 5 Buy Candidates
|Get a PRO membership|
To Reveal Top 5 Buy Candidates
Follow Auto Portfolios gaining up to 30%.
Disclaimer: There is no guarantee against any loss. Your capital is at risk.
Click to become a PRO member